Unique Serum Protein and Metabolic Patterns in Patients with Advanced Clear-Cell Renal Cell Carcinoma Undergoing Sunitinib Treatment: Insights from the Spanish Oncology Genitourinary Group Study - Scorecard - MDSpire

Unique Serum Protein and Metabolic Patterns in Patients with Advanced Clear-Cell Renal Cell Carcinoma Undergoing Sunitinib Treatment: Insights from the Spanish Oncology Genitourinary Group Study

  • By

  • Guillermo Quintás

  • Elena Sanmartín

  • Alicia Garcia-Gimenez

  • José Muñoz-Langa

  • Aida Collado

  • Cristina Suárez

  • Xavier García del Muro

  • María José Méndez-Vidal

  • José García-Sánchez

  • Carmen Salvador-Coloma

  • Nuria Laínez

  • Enrique Gallardo

  • Javier Munárriz

  • Sergio Vázquez

  • Carmen Molins

  • Jaime Font de Mora

  • Gaspar Reynés

  • April 29, 2026

  • 0 min

Share

Clinical Scorecard: Unique Serum Protein and Metabolic Patterns in Patients with Advanced Clear-Cell Renal Cell Carcinoma Undergoing Sunitinib Treatment: Insights from the Spanish Oncology Genitourinary Group Study

At a Glance

CategoryDetail
ConditionMetastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Key MechanismsAngiogenesis and tumor immune escape related to serum proteins and metabolic patterns.
Target PopulationPatients with locally advanced or metastatic CCRCC receiving first-line sunitinib.
Care SettingMulticenter study across ten Spanish hospitals.

Key Highlights

  • Median progression-free survival (PFS) was 9.87 months.
  • Median overall survival (OS) was 21.10 months.
  • Higher IL-6, arginase-1, and S100A9 levels predict shorter OS.
  • Three risk groups identified based on S100A9 and IL-6 levels.
  • Alterations in tryptophan metabolism correlate with OS extremes.

Guideline-Based Recommendations

Diagnosis

  • Measure serum protein levels related to angiogenesis and immune escape.

Management

  • Consider sunitinib as first-line treatment for metastatic CCRCC.

Monitoring & Follow-up

  • Monitor IL-6 and S100A9 levels for prognostic stratification.

Risks

  • Elevated tryptophan metabolites associated with poorer PFS.

Patient & Prescribing Data

Patients with advanced or metastatic CCRCC.

Sunitinib targets the VEGF-A–VEGFR axis and may reverse immune suppression.

Clinical Best Practices

  • Utilize serum biomarkers for patient stratification.
  • Incorporate metabolic profiling in treatment planning.
  • Regularly assess serum protein levels during treatment.

References

Original Source(s)

Unique Serum Protein and Metabolic Patterns in Patients with Advanced Clear-Cell Renal Cell Carcinoma Undergoing Sunitinib Treatment: Insights from the Spanish Oncology Genitourinary Group Study

  • by Guillermo Quintás, Elena Sanmartín, Alicia Garcia-Gimenez, José Muñoz-Langa, Aida Collado, Cristina Suárez, Xavier García del Muro, María José Méndez-Vidal, José García-Sánchez, Carmen Salvador-Coloma, Nuria Laínez, Enrique Gallardo, Javier Munárriz, Sergio Vázquez, Carmen Molins, Jaime Font de Mora, Gaspar Reynés

  • April 29, 2026

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant